Therapy Detail

Therapy Name NS-018
Synonym
Therapy Description

NS-018 inhibits JAK2, including JAK2 V617F, as well as SRC family members, including SRC, FYN, and YES, potentially leading to decreased cell proliferation (PMID: 24413068, PMID: 22829185).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
NS-018 JAK2 Inhibitor - ATP competitive 14 SRC Inhibitor 27 YES Inhibitor 2 NS-018 inhibits JAK2, including JAK2 V617F, as well as SRC family members, including SRC, FYN, and YES, potentially leading to decreased cell proliferation (PMID: 24413068, PMID: 22829185).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
JAK3 A572V acute myeloid leukemia predicted - resistant NS-018 Preclinical - Cell culture Actionable In a preclinical study, an acute myeloid leukemia cell line harboring JAK3 A572V was insensitive to treatment with NS-108 in culture (PMID: 22829185). 22829185
MPL W515L hematologic cancer sensitive NS-018 Preclinical - Cell culture Actionable In a preclinical study, cells expressing MPL W515L were sensitive to treatment with NS-108, demonstrating inhibition of cell growth in culture (PMID: 22829185). 22829185
JAK2 V617F hematologic cancer sensitive NS-018 Preclinical Actionable In a preclinical study, cells expressing JAK2 V617F were sensitive to treatment with NS-108, demonstrating cell growth inhibition and increased apoptotic activity in culture and improved survival in transgenic mouse models (PMID: 22829185). 22829185
ETV6-JAK2 hematologic cancer sensitive NS-018 Preclinical - Cell culture Actionable In a preclinical study, cells expressing ETV6-JAK2 were sensitive to treatment with NS-108, demonstrating inhibition of cell growth in culture (PMID: 22829185). 22829185
ETV6-JAK3 hematologic cancer predicted - resistant NS-018 Preclinical - Cell culture Actionable In a preclinical study, cells expressing ETV6-JAK3 were insensitive to treatment with NS-108 in culture (PMID: 22829185). 22829185
Clinical Trial Phase Therapies Title Recruitment Status